Montefiore Einstein Comprehensive Cancer Center | Strategic Alliance Partners

A comprehensive discussion on combination chemotherapy + immunotherapy regimens available to patients with advanced non–small cell lung cancer.

Shared insight on the value that molecular testing and PD-L1 testing, respectively, have on determining optimal therapy for patients with advanced non–small cell lung cancer.

Switching their focus to advanced non–small cell lung cancer, panelists identify parameters that may influence the use of immune checkpoint inhibitors in this setting.

Switching their focus to the adjuvant setting of resectable NSCLC, expert panelists identify treatment options in this setting and review the clinical data behind them.

Shared insight from key opinion leaders on the value of molecular testing in patients with resectable non–small cell lung cancer and how it can be applied.

Expert oncologists reflect on key factors that aid in the selection of therapy for patients diagnosed with resectable non–small cell lung cancer (NSCLC).

Although the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.

Tumor microenvironment of metastasis doorway density—a biomarker of distant metastatic recurrence—is higher in Black women vs White women with estrogen receptor–positive/HER2-negative breast cancer who have residual disease after neoadjuvant chemotherapy.

Montefiore Einstein Cancer Center hopes to begin combating systemic inequities and improve cancer outcomes for historically disadvantaged populations by taking a data-driven approach to delivering neoadjuvant therapy in communities that are economically and socially marginalized.

Balazs Halmos, MD, discusses the role of immunotherapy in the frontline setting of NSCLC and the emerging pipeline of antibody-drug conjugates that could affect the treatment paradigm in lung cancer.

Balazs Halmos, MD, discusses the importance of testing for HER2 mutations and exon 20 insertions, which are emerging new targets in non–small cell lung cancer, and how fam-trastuzumab deruxtecan-nxki meets needs for patients with HER2-mutant disease.

Balazs Halmos, MD, discusses the significance of the FDA approval of tremelimumab-actl plus durvalumab and chemotherapy in patients with metastatic non–small cell lung cancer.

The American Cancer Society has awarded Montefiore Einstein Cancer Center more than $2.1 million to support cancer research and reduce individual and systematic barriers that prevent people from accessing cancer care.

The National Cancer Institute-designated Montefiore Einstein Cancer Center has partnered with the Price Family Foundation to fund 8 research teams developing novel cancer therapies and improving cancer outcomes for historically marginalized communities in the Bronx.

Research investigating the physical and mental health consequences of being at the World Trade Center site during and after the terrorist attacks has been instrumental in obtaining health care coverage for thousands of individuals.

Investigators at the Montefiore Einstein Cancer Center report that Black and Hispanic patients had outcomes and side effects following CAR-T treatment that were comparable to their white and Asian counterparts, according to findings from a study published in Bone Marrow Transplantation.

Lung cancer remains the most common cause of cancer death in the United States.

Fewer African American and Hispanic patients participated in oncology trials from 2003 to 2016 than from 1996 to 2002.

The National Cancer Institute-designated Albert Einstein Cancer Center has announced the appointment of three faculty members to key leadership positions.

The idea to provide wearable devices to my patients first came to me 6 years ago at a charity spinning event.

The Cancer Dormancy and Tumor Microenvironment Institute, which has recently been launched at Albert Einstein Cancer Center, will focus on taking the tumor microenvironment research being done at the center to the next level and to develop novel technologies that can better identify dormant cancer as well as prevent and control recurrent disease.

Julio Aguirre-Ghiso, PhD, discusses future research directions being conducted by investigators at the Albert Einstein Cancer Center.

Edward Chu, MD, MMS, discusses ongoing efforts to address disparities in lung cancer at Montefiore and Albert Einstein College of Medicine.

Montefiore Einstein Cancer Center has once again earned national recognition for its quality of care studies leading to enhanced patient care, its strong cancer screening and early detection initiatives, and its exceptional support services.

Balazs Halmos, MD, MS, discusses a study examining the effectiveness of COVID-19 vaccination in patients with cancer and identified important areas for future research.

The field of targeted therapy for patients with non–small cell lung cancer has grown exponentially in recent years, with inhibitors for RET, MET exon 14 skipping, and KRAS G12C mutations transforming the paradigm.

Albert Einstein Cancer Center, Albert Einstein College of Medicine, and Montefiore Health System announced that Lauren Hackett, MPA, has been appointed the deputy director of administration of AECC and associate vice president of cancer medicine at Montefiore Medicine.

Dr. Halmos discusses the data from a study examining seroconversion rates following COVID-19 vaccination among patients with cancer and underscores the need for novel vaccination or passive immunization strategies for immunosuppressed cohorts.

Leading cancer biologist Julio Aguirre-Ghiso, PhD, has been named founding director of the Cancer Dormancy and Tumor Microenvironment Institute, director of the Gruss-Lipper Biophotonics Center, and co-leader of the AECC Tumor Microenvironment and Metastasis Program.

Nitin Ohri, MD, discusses the role of chemoradiation therapy in locally advanced non–small cell lung cancer.